The global epinephrine autoinjector market comprises prefilled syringes or injector devices containing the drug epinephrine that can be used in emergency situations to treat sudden onset of allergic reactions like anaphylaxis. Epinephrine autoinjectors provide patient-controlled, needle-based epinephrine drug delivery to counter severe symptoms of allergic reactions. These single-dose devices are easy-to-use, compact, and intended for self-administration rather than administration by trained medical professionals.
The Global Epinephrine Autoinjector Market is estimated to be valued at US$ 3.91 Bn in 2024 and is expected to exhibit a CAGR of 8.6% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the global epinephrine autoinjector market are Mylan, Teva Pharmaceutical, Impax Laboratories, Adamis Pharmaceuticals Corporation, Pfizer, ALK Abello, Lincoln Medical, Hospira, Sanofi, Kaleo. Key players Mylan and Teva Pharmaceutical collectively hold a dominant share of over 85% in the global market.
The increasing prevalence of food allergies, insect stings, and drug allergies is expected to drive the demand for Global Epinephrine Autoinjector Market Share during the forecast period. According to Allergy Asthma Network, food allergies affect approximately 32 million Americans annually. Availability of generic versions of the devices after patent expiry of brand names is another factor fueling market growth.
Geographic expansion into emerging countries and improving access through initiatives undertaken by key players are factors behind the global expansion of the epinephrine autoinjector market. Players are focusing on innovative device features, variants with extended shelf life, alternative epinephrine delivery technologies.
Market Key Trends
One of the key trends driving growth of the global epinephrine autoinjector market is the increasing accessibility of products to patients. Manufacturers are undertaking various strategies like tiered pricing, patient assistance programs, and collaborations with government agencies and non-profit organizations to make epinephrine autoinjectors affordable and available to a larger patient base globally. For example, Mylan launched a generic 0.15mg and 0.3 mg epinephrine injection under the “Authorized Generic” in the U.S to improve accessibility.
Porter’s Analysis
Threat of new entrants: Low barriers to enter the autoinjector market as autoinjector technology is relatively unpatented but significant capital costs for manufacturing facilities pose threat.
Bargaining power of buyers: Moderate bargaining power of buyers as large pharmaceutical companies dominate the autoinjector market and buyers have few alternatives.
Bargaining power of suppliers: Moderate bargaining power for raw material suppliers but high for autoinjector device suppliers and formulation technology providers as their expertise create vendor lock-ins.
Threat of new substitutes: Low threat as no clear substitute available for epinephrine autoinjectors used to treat severe allergic reactions.
Competitive rivalry: High due to presence of major players like Mylan, Teva, and Adamis fighting for market share through product differentiation and marketing.
Geographical Regions
North America currently holds the major share of the global epinephrine autoinjector market in terms of value due to high incidence of anaphylaxis in the region and favorable reimbursement policies for epinephrine autoinjectors. The United States alone contributes over 80% of the North American market value.
Asia Pacific is expected to be the fastest growing regional market for epinephrine autoinjectors during the forecast period due to increasing awareness about treatment of allergic emergencies, rising healthcare expenditure, and growing incidence of food allergies in countries like China, India, and Japan.